Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2014 1
2015 1
2016 1
2019 1
2020 3
2021 7
2022 3
2023 9
2024 12
2025 35
2026 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, van der Meulen NP. Müller C, et al. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930. doi: 10.1007/s00259-019-04345-0. Epub 2019 May 27. Eur J Nucl Med Mol Imaging. 2019. PMID: 31134301 Free PMC article.
Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177.
Trejtnar F, Bárta P, Kozempel J, Vlk M, Ďurinová A, Kuchařová M, Pávek P. Trejtnar F, et al. Nucl Med Biol. 2025 May-Jun;144-145:108998. doi: 10.1016/j.nucmedbio.2025.108998. Epub 2025 Feb 12. Nucl Med Biol. 2025. PMID: 39978166 Review.
Recent experimental data suggests that terbium-161 might well follow the example of lutetium-177 regarding applicability in nuclear medicine. Similarly to lutetium-177, the terbium-161 emits beta particles and gamma-radiation, although terbium- …
Recent experimental data suggests that terbium-161 might well follow the example of lutetium-177 regarding applicability in nu …
First-in-human results of terbium-161 [(161)Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
Buteau JP, Kostos L, Jackson PA, Xie J, Haskali MB, Alipour R, McIntosh LE, Emmerson B, MacFarlane L, Martin CA, Chan J, Williams SE, Jewell KE, Eifer M, Hamilton AJ, Harris WQ, Akhurst T, Au L, Cardin AJ, Furic L, Kashyap RK, Kong G, Ravi Kumar AS, Murphy DG, Ravi R, Saghebi J, Sandhu S, Tran B, Azad AA, Hofman MS. Buteau JP, et al. Lancet Oncol. 2025 Aug;26(8):1009-1017. doi: 10.1016/S1470-2045(25)00332-8. Epub 2025 Jul 3. Lancet Oncol. 2025. PMID: 40617237 Clinical Trial.
BACKGROUND: Terbium-161 ((161)Tb) emits beta-radiation similar to lutetium-177 ((177)Lu), with additional radiation over ultra-short path lengths from Auger electrons. (161)Tb has shown superior in-vitro and in-vivo efficacy compared with (177)Lu. ...
BACKGROUND: Terbium-161 ((161)Tb) emits beta-radiation similar to lutetium-177 ((177)Lu), with additional radiation over ultra …
Alpha and Beta Radiation for Theragnostics.
Song H, Sgouros G. Song H, et al. PET Clin. 2024 Jul;19(3):307-323. doi: 10.1016/j.cpet.2024.03.006. Epub 2024 Apr 29. PET Clin. 2024. PMID: 38688775 Review.
Radiotheranostic landscape: A review of clinical and preclinical development.
Tran HH, Yamaguchi A, Manning HC. Tran HH, et al. Eur J Nucl Med Mol Imaging. 2025 Jun;52(7):2685-2709. doi: 10.1007/s00259-025-07103-7. Epub 2025 Feb 1. Eur J Nucl Med Mol Imaging. 2025. PMID: 39891713 Review.
Next-generation therapeutic radionuclides, such as the beta-emitter terbium-161 and alpha-emitters actinium-225 and lead-212, are under investigation to complement or replace lutetium-177, addressing the need for improved efficacy and reduced toxicity. ...
Next-generation therapeutic radionuclides, such as the beta-emitter terbium-161 and alpha-emitters actinium-225 and lead-212, …
(161)Terbium-Labeled Gold Nanoparticles as Nanoscale Brachytherapy Agents Against Breast Cancer.
Salvanou EA, Apostolopoulou A, Xanthopoulos S, Koelewijn S, van Overeem P, Laurent G, Bazzi R, Denat F, Roux S, Bouziotis P. Salvanou EA, et al. Materials (Basel). 2025 Jan 8;18(2):248. doi: 10.3390/ma18020248. Materials (Basel). 2025. PMID: 39859720 Free PMC article.
Due to their intriguing emission profile, Terbium-161 ((161)Tb) radiopharmaceuticals seem to bring significant advancement in theranostic applications to cancer treatment. ...
Due to their intriguing emission profile, Terbium-161 ((161)Tb) radiopharmaceuticals seem to bring significant advancement in …
Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.
Ntihabose CM, Handula M, Piet A, Beekman S, van Dalen L, Eskandari N, Aydogan A, Stuurman D, de Ridder C, Konijnenberg M, Seimbille Y, de Blois E. Ntihabose CM, et al. EJNMMI Radiopharm Chem. 2025 Oct 3;10(1):64. doi: 10.1186/s41181-025-00390-3. EJNMMI Radiopharm Chem. 2025. PMID: 41042285 Free PMC article.
Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.
Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Köster U, Schibli R, van der Meulen NP, Müller C. Borgna F, et al. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1113-1126. doi: 10.1007/s00259-021-05564-0. Epub 2021 Oct 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 34625828 Free PMC article.
PURPOSE: The beta( )-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (D …
PURPOSE: The beta( )-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in kil …
Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting.
Busslinger SD, Mapanao AK, Kegler K, Bernhardt P, Flühmann F, Fricke J, Zeevaart JR, Köster U, van der Meulen NP, Schibli R, Müller C. Busslinger SD, et al. Eur J Nucl Med Mol Imaging. 2024 Nov;51(13):4049-4061. doi: 10.1007/s00259-024-06827-2. Epub 2024 Jul 24. Eur J Nucl Med Mol Imaging. 2024. PMID: 39046521 Free PMC article.
Impressive preclinical data obtained with [(161)Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as an alternative to lutetium-177. The aim of the present study was to compare the tolerability of (161)Tb- and (177)Lu-based DOTA-LM3 and DOT …
Impressive preclinical data obtained with [(161)Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as …
88 results